Hanmi Science FY 2025 Annual Report
Beta

Filed: March 20, 2026· period ending December 31, 2025DART

Hanmi Science annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 20, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Hanmi Science FY 2025 Annual Report Analysis

Business Overview

• Business model: holding company with revenue from equity method income, patent/trademark royalties, healthcare products, and pharmaceutical wholesale totaling KRW 1.36T in FY2025
• November 2022 acquisition and integration of Hanmi Healthcare added medical devices, food manufacturing/distribution, beauty care, and pharma IT solutions segments

Management Discussion & Analysis

• Revenue KRW 1.357T (+5.7% YoY), operating profit KRW 138.7B (+40.3%), net income KRW 117.7B (+107.6%)
• Healthcare segment revenue KRW 155.1B (+19.8%), operating profit KRW 23.1B (+21.2%) driven by medical device and consumer health product sales increase

Risk Factors

• Hanmi Science group 10% KRW/USD move → ±KRW 1.64B pre-tax earnings impact, up from ±KRW 0.61B prior year
• Hanmi Pharm 10% KRW/USD move → ±KRW 15.65B pre-tax earnings impact, up from ±KRW 13.36B prior year

Hanmi Science FY 2025 Key Financial Metrics
DART

Total Assets

KRW 1.49T

▲ +10.4% YoY

Operating Cash Flow

KRW 47.7B

▼ -42.6% YoY

Source: KIFRS consolidated financial data from Hanmi Science annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding